Update

COVID-19 Pandemic–Associated Changes in Emergency Department Visits

United States, December 2020-January 2021

Jennifer Adjemian, PhD; Kathleen P. Hartnett, PhD; Aaron Kite-Powell, MS; Jourdan DeVies, MS; Roseric Azondekon, PhD; Lakshmi Radhakrishnan, MPH; Katharina L. van Santen, MSPH; Loren Rodgers, PhD

Disclosures

Morbidity and Mortality Weekly Report. 2021;70(15):552-556. 

In This Article

Abstract and Introduction

Introduction

During March 29–April 25, 2020, emergency department (ED) visits in the United States declined by 42% after the declaration of a national emergency for COVID-19 on March 13, 2020. Among children aged ≤10 years, ED visits declined by 72% compared with prepandemic levels.[1] To assess the continued impact of the COVID-19 pandemic on EDs, CDC examined trends in visits since December 30, 2018, and compared the numbers and types of ED visits by patient demographic and geographic factors during a COVID-19 pandemic period (December 20, 2020–January 16, 2021) with a prepandemic period 1 year earlier (December 15, 2019–January 11, 2020). After an initial decline during March–April 2020,[1] ED visits increased through July 2020, but at levels below those during the previous year, until December 2020–January 2021 when visits again fell to 25% of prepandemic levels. During this time, among patients aged 0–4, 5–11, 12–17, and ≥18 years, ED visits were lower by 66%, 63%, 38%, and 17%, respectively, compared with ED visits for each age group during the same period before the pandemic. Differences were also observed by region and reasons for ED visits during December 2020–January 2021; more visits during this period were for infectious diseases or mental and behavioral health–related concerns and fewer visits were for gastrointestinal and upper-respiratory–related illnesses compared with ED visits during December 2019–January 2020. Although the numbers of ED visits associated with socioeconomic factors and mental or behavioral health conditions are low, the increased visits by both adults and children for these concerns suggest that health care providers should maintain heightened vigilance in screening for factors that might warrant further treatment, guidance, or intervention during the COVID-19 pandemic.

Data were obtained from the National Syndromic Surveillance Program (NSSP),* a collaborative system developed and maintained by CDC, state and local health departments, and academic and private sector health partners. NSSP collects electronic health data in near real-time, including ED visits from a subset of hospitals in 49 states (all but Hawaii) and the District of Columbia. This study analyzed information collected from approximately 71% of nonfederal facilities, nationwide, using data for all ED visits from participating hospitals in the 46 states that reported ED visits consistently during the prepandemic (December 15, 2019–January 11, 2020) and pandemic (December 20, 2020–January 16, 2021) periods assessed. All hospitals in Hawaii, Ohio, South Dakota, and Wyoming, and hospitals in other states that started or stopped reporting during 2019–2021 were excluded. Patient diagnoses were analyzed using a subset of records that included at least one specific, billable International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code. Facilities that did not report diagnostic codes consistently or reported incomplete codes during 2019–2021 were excluded. ED visits were categorized using the Clinical Classifications Software Refined tool from the Healthcare Cost and Utilization Project, which combines ICD-10-CM codes into clinically meaningful groups.[2]

This analysis was limited to the top 200 diagnostic categories (pediatric = 455 total diagnostic categories; adult = 497 total diagnostic categories) for each patient-level category evaluated during the assessed periods. The 10 categories with the highest and lowest significant (p<0.05) prevalence ratios (PRs) were identified. Trends in ED visits during December 30, 2018–January 16, 2021 were examined; overall analysis of trends focused on the prepandemic period during December 15, 2019–January 11, 2020 and the pandemic period during December 20, 2020–January 16, 2021, with comparisons by patient sex, age, U.S. Department of Health and Human Services (HHS) region,§ and reason for the visit. Estimates of weekly change and PRs were calculated to assess differences in numbers of ED visits between the two periods. All analyses were conducted using R software (version 4.0.; The R Foundation) This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.**

After decreasing by 42% during March–April 2020,[1] overall U.S. ED visits increased through July 2020 then stabilized in August 2020 at levels 15% below those during the same prepandemic period. During December 2020–January 2021, numbers of visits declined again to a level 25% lower than those during the previous year (December 2019–January 2020) (Figure), including a 23% decline in visits by males and a 27% decline in visits by females. During December 2020–January 2021, the numbers of ED visits in all age groups were lower than were those during the prepandemic period. The largest observed decline in visits was among children, especially those aged 0–4 years (66%) and 5–11 years (63%) (Supplementary Figure 1, https://stacks.cdc.gov/view/cdc/104808). ED visits by adults aged ≥18 years were 17% lower than ED visits during the prepandemic period (Figure). During December 2020–January 2021, ED visits varied by HHS region, ranging from an overall 29% decrease in the upper Midwest to a 21% decrease in the Northeast. ED visits by adults and pediatric patients declined in all regions (Supplementary Figure 2, https://stacks.cdc.gov/view/cdc/104808), ranging from a 23% decrease in the West (Region 9) to a 14% decrease in the Northeast (Region 3) among adults, and from 65% in the Northeast (Region 2) to 53% in the Midwest (Region 7) among children.

Figure.

Weekly number of total,* adult, and pediatric§ emergency department (ED) visits and COVID-19–like illness visits — National Syndromic Surveillance Program, United States, December 30, 2018–January 16, 2021
*Total, adult, and pediatric visits include visits for COVID-19–like illness.
Patients aged ≥18 years.
§Patients aged <18 years.
Forty-six states and the District of Columbia. All facilities in Hawaii, Ohio, South Dakota, and Wyoming, and facilities in other states that started or stopped reporting to the National Syndromic Surveillance Program during 2019–2021 were excluded.

During December 2020–January 2021, the proportion of ED visits for infectious disease–related concerns (i.e., exposure, encounters, screening, or contact with infectious disease) was higher than that during the same period before the pandemic for adults (PR = 5.86) and children (PR = 9.22), as were the proportion of visits related to socioeconomic and psychosocial (mental and behavioral health–related concerns) factors (adults PR = 1.37; children PR = 2.56). Among adults, the proportion of ED visits during this period was also higher than that during the prepandemic period for menopausal disorders (PR = 1.89); respiratory failure, insufficiency, and arrest (PR = 1.62); acute pulmonary embolism (PR = 1.59); cardiac arrest and ventricular fibrillation (PR = 1.45); malaise and fatigue (PR = 1.34); acute and unspecified renal failure (PR = 1.33); and symptoms of mental and substance-use conditions (PR = 1.28) (Table 1). Among children, the proportion of ED visits during this period was higher compared with the prepandemic period for calculus of the urinary tract (PR = 2.70); open wounds to limbs, subsequent encounter (PR = 2.67); suicidal ideation, attempt, and intentional self-harm (PR = 2.64); sexually transmitted infections (HIV and viral hepatitis) (PR = 2.57); schizophrenia spectrum and other psychotic disorders (PR = 2.55); lifestyle and life management factors (e.g., tobacco use, lack of physical exercise, high-risk sexual behavior, sleep deprivation or insomnia, or stress or burnout) (PR = 2.55); feeding and eating disorders (PR = 2.52); and open wounds of the head and neck, subsequent encounter (PR = 2.51) (Table 2). Decreases in the proportion of ED visits related to gastrointestinal and upper respiratory–related factors were identified in both adults and children, with the largest declines among children for influenza (PR = 0.01), acute bronchitis (PR = 0.17), pneumonia except that caused by tuberculosis (PR = 0.30), otitis media (0.36), and sinusitis (PR = 0.42).

*https://www.cdc.gov/nssp/index.html
PR and associated 95% confidence interval of visits was calculated for each diagnostic category as the proportion of ED visits during the pandemic period (December 20, 2020–January 16, 2021) divided by the proportion of visits during the comparison prepandemic period (December 15, 2019–January 11, 2020) ([ED visits in diagnostic category in pandemic period/all ED visits in pandemic period]/[ED visits in diagnostic category in comparison period/all ED visits in comparison period]).
§HHS Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont; Region 2: New Jersey, New York. Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, and Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, and Texas; Region 7: Iowa, Kansas, Missouri, and Nebraska; Region 8: Colorado, Montana, North Dakota, and Utah; Region 9: Arizona, California, Nevada; Region 10: Alaska, Idaho, Oregon, and Washington.
The weekly change in ED visits during the pandemic and comparison prepandemic periods was calculated as the difference in total counts between the two periods, divided by 4 weeks ([visits (pandemic period) in diagnostic category – visits (comparison period) in diagnostic category]/4).
**45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....